Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMD

Kodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneration.

The Phase 3 study met its primary endpoint, showing similar visual acuity outcomes and safety profile to Eylea, positioning Zenkuda as a potential alternative for patients with the disease.

The news sent Kodiak’s shares sharply higher, reflecting investor optimism about the company’s ability to capture market share in the lucrative ophthalmology space.

Analysts note that a successful regulatory filing could further boost the company’s valuation, though final approval will depend on additional data and review.